Rocuronium (Zemuron)

Question 1

Rocuronium Classification

Answer 1

Non-depolarizing neuromuscular blocker

Question 2

Rocuronium Mechanism of Action

Answer 2

Nicotinic ACh R-antagonist -> competes with ACh at neuromuscular junction and prevents binding thus inhibiting skeletal muscle depolarization

Question 3

Rocuronium Pharmacokinetics

Answer 3

Onset: 60-70s
Peak: 1-3m
Duration: 25-40m
Half Life: 14-18m

Question 4

Rocuronium Indications/Field Use

Answer 4

• Need for temporary paralysis to facilitate endotracheal intubation
• Need for continued paralysis following endotracheal intubation

Question 5

Rocuronium Contraindications

Answer 5

Hypersensitivity

Question 6

Rocuronium Side Effects/Adverse Reactions

Answer 6

Tachycardia, HTN, hypotension, bronchospasm (rarely)

Question 7

Rocuronium Dose

Answer 7

Adult:
0.6-1.2mg/kg IV, IO
Pedi:
0.6mg/kg IV, IO

Question 8

Rocuronium Precautions

Answer 8

Presence of neuromuscular diseases may be associated with prolonged paralysis

Question 9

Rocuronium Drug Interactions

Answer 9

Potentiated by lidocaine, procainamide, β-blockers, K-sparing diuretics, magnesium sulfate, and other neuromuscular blockers including succinylcholine